Nonvalvular atrial fibrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin has been used to prevent AF-associated stroke for more than 50 years, non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban recently have been developed to overcome the disadvantages of warfarin. Based on the results of NOAC clinical trials, Savelieva and Camm made recommendations regarding selection of NOACs in patients with nonvalvular AF. Recent accumulating evidence indicates that NOACs work differently in Asian and non-Asian individuals. In this review, we discuss the results of the large, randomized, phase 3 international clinical trials on NOACs, the subanalyses of Asians, and a Japanese phase 3 clinical trial of rivaroxaban to discriminate Japanese patient-specific characteristics with regard to their responses to NOACs and make recommendations. Our analysis revealed that rivaroxaban decreased the incidence of gastrointestinal (GI) bleeding compared with warfarin in Japanese patients. The efficacy results showed that rivaroxaban significantly decreased the incidence of ischemic stroke (hazard ratio: 0.40, 95% confidence interval: 0.17-0.96) compared with warfarin. The lower incidence of GI bleeding and ischemic stroke may be specific to Japanese patients. Based on the present and previous results, the following recommendations regarding the selection of NOACs are added in the Camm chart for Japanese patients: edoxaban for patients with a high risk of bleeding and those with a previous stroke; and rivaroxaban for patients with a high risk of ischemic stroke and a low bleeding risk, and those with previous GI bleeding.
| INTRODUCTION
Nonvalvular atrial fibrillation (AF) is known as a risk factor for stroke.
It was reported that approximately 20% of hospitalized patients with ischemic stroke in Japan had AF complications. 1 Warfarin has been used to prevent AF-associated stroke for more than 50 years, but warfarin treatment is a burden for patients and physicians because it requires a dose adjustment achieved by monitoring the prothrombin
time-international normalized ratio (PT-INR). Warfarin also interacts
with food and many other drugs.
Non-vitamin K antagonist oral anticoagulants (NOACs) were developed to overcome these disadvantages of warfarin, and the effi- condition. 2 However, because the chart was created based on the results of international collaborative clinical trials, it must be used carefully for Japanese patients.
First, the therapeutic range of warfarin's PT-INR for Japanese patients is different from that for patients in other countries. The range of 1.6 to 2.6 is recommended for Japanese elderly patients (age ≥70 years), whereas a range of 2.0 to 3.0 is recommended in the EU and US guidelines. 3 This difference in the therapeutic range in INR is based on the higher incidence of warfarin-related intracranial hemorrhage (ICH) in Asians, including Japanese. 4 Based on the present review, therefore, we propose a method for selecting NOACs for Japanese patients with AF based on the results of subanalyses of Asian patients in the following clinical trials:
Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY), 5 Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), 6 and Apixaban for
Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), 7 as well as the Japanese-ROCKET AF (J-ROCKET AF) study in which Japanese patients participated. 8 Edoxaban was approved for stroke prevention in patients with AF (SPAF) in 2014 in Japan, and it is not yet included in the Camm chart. In the present review, we discuss the characteristics, efficacy, and safety of edoxaban and 3 other NOACs: dabigatran, rivaroxaban, and apixaban.
| CHARACTERISTICS OF THE NOACS
The characteristics of the 4 NOACs (edoxaban, dabigatran, rivaroxaban, and apixaban) have been compared with those of warfarin and reported in numerous studies. [9] [10] [11] [12] [13] [14] [15] [16] In brief, NOACs have shorter halflives and take less time to reach maximum blood concentration than does warfarin. Unlike warfarin, NOACs have a specific target (either thrombin or factor Xa), do not require coagulation monitoring, and can be administered with fixed doses.
| EVIDENCE FROM INTERNATIONAL CLINICAL TRIALS
The summary of key patient characteristics and findings from the 4 phase 3 clinical trials of NOACs are described in previous studies, [17] [18] [19] [20] [21] and major differences are also summarized in the 22 The results of the ROCKET AF study also showed that the incidence of major bleeding from a gastrointestinal (GI) site in the rivaroxaban group (3.2%) was significantly higher than that in the warfarin group (2.2%) (P < 0.001). In addition, the incidence of major bleeding in the rivaroxaban group relative to the warfarin group tended to be higher HRs are for the NOAC group as compared with the warfarin group. 1 Major bleeding from GI site: 224 bleeding events (3.2%) in the rivaroxaban group, as compared with 154 events in the warfarin group (2.2%; P < 0.001).
(HR: 0.87, 97.5% CI: 0.73-1.04, P = 0.08) for decreasing the incidence of stroke or SE compared with warfarin was reported. However, the HR at 30 mg qd was slightly higher than that at 60 mg qd. Dabigatran at 150 mg bid was superior to warfarin in decreasing the incidence of stroke or SE (P < 0.001), and it was noninferior to warfarin at 110 mg bid (HR: 0.90, 95% CI: 0.74-1.10, P = 0.30). 19, 20 Although dabigatran at 150 mg bid significantly lowered the incidence of ischemic stroke compared with warfarin (HR: 0.76, 95% CI: 0.60-0.98, P = 0.03), dabigatran at 110 mg bid did not (HR: 1.11, 95% CI:
0.89-1.40, P = 0.35). Overall, dabigatran at 110 mg bid significantly lowered the incidence of major bleeding compared with warfarin (P = 0.003); however, when the bleeding incidence is analyzed by bleeding sites, dabigatran increased the incidence of GI bleeding both at 110 mg bid (HR: 1.10, 95% CI: 0.86-1.41, P = 0.43) and 150 mg bid (HR: 1.50, 95% CI: 1.19-1.89, P < 0.001). The incidence of GI bleeding with dabigatran 150 mg bid was highly increased.
The ARISTOTLE study showed that apixaban significantly reduced the incidence of stroke or SE compared with warfarin (P = 0.01). 22 Apixaban also significantly reduced the incidence of both major bleeding (HR: 0.69, 95% CI: 0.60-0.80, P < 0.001) and ICH (HR: 0.42, 95% CI: 0.30-0.58, P < 0.001). The noninferiority of apixaban to warfarin regarding GI bleeding (HR: 0.89, 95% CI: 0.70-1.15, P = 0.37) was also shown in the ARISTOTLE study.
| FINDINGS FROM SUBANALYSES OF ASIANS FROM THE INTERNATIONAL CLINICAL TRIALS
The proportion of Asian patients with a history of stroke was higher than that of non-Asian patients. 23 Three NOACs (dabigatran, rivaroxaban, and apixaban) and warfarin showed a higher incidence of stroke in Asians compared with non-Asians ( Figure 1A ,B), suggesting that stroke occurs more often in Asians. Warfarin also increased the incidence of major bleeding in Asians compared with non-Asians, but 3 NOACs reduced major bleeding more in Asians than non-Asians ( Figure 1C,D) , indicating that warfarin tends to cause major bleeding in Asians. The incidence of ICH in Asians was higher with any of the drugs tested than that in non-Asians; however, whereas warfarin increased the ICH incidence 3-fold, the 3 NOACs doubled the incidence. [5] [6] [7] These studies supported the results of previous epidemiological studies, in which an increased incidence of warfarin-related ICH was shown in Asian populations. 4 
| FINDINGS FROM THE JAPANESE PHASE 3 CLINICAL TRIAL
There are 2 important differences between the J-ROCKET AF and ROCKET AF studies. 8 First, the rivaroxaban dose in the J-ROCKET AF study (15 mg qd) was lower than that in the EU and US (20 mg qd), because the pharmacokinetic data (C max , area under the curve) of rivaroxaban in Japanese patients who received rivaroxaban at 15 mg qd were observed to be comparable with those of Caucasian patients who received rivaroxaban at 20 mg qd. 24 For Japanese patients, the dose is further reduced to 10 mg qd if renal function is impaired (with a creatinine clearance of 30-49 mL/min). Second, in the J-ROCKET AF study, warfarin with the INR 1.6 to 2.6 is recommended in patients age ≥70 years, as in the Japanese guideline, 3 instead of the INR of 2.0 to 3.0 as used in the European Union and United States.
In the J-ROCKET AF study, the safety data showed that there was no significant difference between rivaroxaban and warfarin in the incidences of major bleeding (HR: 0.85, 95% CI: 0.50-1.43) or death caused by bleeding (HR: 0.33, 95% CI: 0.03-3.14). 8 However,
when the results were analyzed by the bleeding site, several advantages were found in Japanese patients, including that rivaroxaban decreased the incidence of GI bleeding by approximately 50% compared with warfarin. Because the incidence of GI bleeding (P < 0.001) was lower in the warfarin group than in the rivaroxaban group in the global clinical trial ROCKET AF study, the lower GI bleeding in the rivaroxaban group appears to be specific to Japanese patients ( Figure 2 ). Rivaroxaban also decreased the ICH rate in Japanese patients compared with warfarin (rivaroxaban 0.65%/y, warfarin
1.32%/y). It should, however, be noted that the possibility of a lack of robustness of the outcome analysis in the J-ROCKET AF study FIGURE 2 Major bleeding rates by sites in the J-ROCKET AF and ROCKET AF studies. 8 could not be excluded because of the small sample size of the Japanese cohort used in the study. 8 Although difference in the primary efficacy endpoint (all-cause stroke plus non-central nervous system SE; HR: 0.49, 95% CI: 0.24-1.00, P = 0.050) was not significant, rivaroxaban significantly decreased the incidence of all-cause stroke (HR: 0.46, 95% CI: 0.22-0.98) compared with warfarin. 8, 25 Rivaroxaban also significantly decreased the incidence of ischemic stroke (HR: 0.40, 95% CI: 0.17-0.96) compared with warfarin in Japanese patients, whereas in the global ROCKET AF study, the incidence data were HR: 0.94 and 95%
CI: 0.75-1.17, suggesting that the lower incidence in ischemic stroke with rivaroxaban may be specific to Japanese patients.
| RECOMMENDATIONS FOR THE SELECTION OF NOACS IN JAPAN
Since edoxaban was approved for SPAF in 2014 in Japan, we reviewed the results of the ENGAGE AF-TIMI 48 study and the phase 3 Japanese study (J-ROCKET AF study) to investigate whether there are any Japanese-specific traits in the Camm chart. 2 Based on the results, we propose the following Japanese version of the Camm chart ( Figure 3 ).
In the Japanese version of the Camm chart, rivaroxaban is excluded from administration to patients with a high risk of bleeding Rivaroxaban is also recommended for patients with coronary artery disease, a previous myocardial infarction (MI), or a high risk for ACS/MI, as the results of the ATLAS ACS2-TIMI51 study showed that rivaroxaban significantly decreased the rate of death due to cardiovascular events, MI, and stroke compared with placebo (HR: 0.84, 95% CI: 0.74-0.96, P = 0.008). 22 However, rivaroxaban doses tested in ATLAS ACS2-TIMI 51 were lower than therapeutic doses for prevention of AF-related stroke (2. For patients with renal impairment, apixaban at 2.5 mg bid and rivaroxaban at 10 mg qd would be more appropriate because the respective renal clearances were 27% and 35%. 12 At present, edoxaban is not included in the Japanese version of the Camm chart because the relevant data are not yet published.
| CONCLUSION
In Japan, 4 NOACs-dabigatran, rivaroxaban, apixaban, and edoxaban-are currently approved for SPAF. It is important to understand the differences between these NOACs and warfarin to maximize the benefit of NOACs in patients with AF. Savelieva and Camm made recommendations on the selection of NOACs (dabigatran, rivaroxaban, and apixaban) depending on patient characteristics. 2 However, because studies have found that the stroke incidence and bleeding incidence caused by warfarin and NOACs in Japanese patients differ from those in non-Japanese patients, a Japanese version of the Camm chart is proposed in this report, based on the clinical trial data. At this time, postmarketing surveillance of rivaroxaban in Japan shows no notable difference in safety and efficacy compared with the findings from the previous clinical trials. 29 Currently ongoing provide ethnicity-specific differences. 30 
